Electrophysiological Effects of Guanfacine Extended-Release (GXR) on Inhibitory Control in Children With Attention Deficit/Hyperactivity Disorder (ADHD).

Trial Profile

Electrophysiological Effects of Guanfacine Extended-Release (GXR) on Inhibitory Control in Children With Attention Deficit/Hyperactivity Disorder (ADHD).

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2012

At a glance

  • Drugs Guanfacine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Feb 2012 Actual patient number is 42 according to ClinicalTrials.gov.
    • 16 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jul 2011 Planned End Date changed from 1 May 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top